Journal September 25, 2026 6 min read

What markers track hyperpigmentation?

Hyperpigmentation is tracked through a mix of clinical scoring scales, colorimetric and spectrophotometric measurement of melanin, and molecular readouts of melanogenesis such as tyrosinase activity and MITF expression.

peptides-pro Editorial

Hyperpigmentation is an umbrella term for acquired disorders in which melanin is overproduced or unevenly distributed in the skin, and the markers used to track it fall into three broad classes: clinical severity scales, instrument-based colour measurements, and molecular readouts of the melanogenic machinery. The clinical literature on melasma, post-inflammatory hyperpigmentation (PIH) and facial dark spots uses validated visual instruments such as the patient observer scar assessment scale (POSAS) alongside colorimetry to quantify vascularity and pigmentation relative to surrounding skin [6]. Molecular work centres on the tyrosinase enzyme and the MITF transcription factor as the regulatory nodes through which depigmenting agents are assessed [5].

Identifiers vary by the specific marker rather than by the condition. Tyrosinase is the rate-limiting enzyme in melanin synthesis and is the target named in the Curcuma xanthorriza Roxb. trial, which describes the plant as operating by inhibiting tyrosinase and reducing MITF transcription [5]. Kojic acid is described in the same functional class, as a natural hypopigmenting agent whose delivery challenges have driven nanotechnology-based formulation strategies [12]. No sequence, formula or molecular weight is supplied by the evidence block for any of these markers.

Research Studies

Tyrosinase and MITF in Curcuma xanthorriza Roxb. cream for melasma

A registered trial of a 10% Curcuma xanthorriza Roxb. cream frames melasma as an acquired hyperpigmentation disorder with multifactorial aetiology and a high recurrence rate, and notes that hydroquinone remains the first-line depigmentation agent despite frequent adverse effects [5]. The rationale for the investigational cream is stated mechanistically: the plant inhibits tyrosinase and reduces MITF transcription [5]. These are the molecular markers the study design treats as relevant to pigment reduction.

Melanin synthesis inhibition and bakuchiol in post-inflammatory hyperpigmentation

PIH is described as an acquired hypermelanosis arising after cutaneous inflammation or injury, occurring frequently in darker-skinned individuals [8]. Bakuchiol, a plant-derived compound, is reported to have inhibitory effects on melanin synthesis, which the investigators position as the basis for testing it in PIH using a previously validated model and comparing it against acne-induced PIH [8].

Colorimetry and POSAS in sun protection and linear repair of surgical defects

A randomized split-wound study is designed to test whether zinc-containing sunscreen influences the aesthetic outcome of scars after linear repair of Mohs micrographic surgery defects [6]. Half of each wound receives sunscreen and half does not. At three months, assessment uses POSAS and a colorimeter to measure vascularity and hyperpigmentation in the treated and untreated areas compared with surrounding skin [6]. This design makes explicit that pigmentation and vascularity are separable, instrument-measured endpoints.

Pigment-targeting laser wavelength and oral tranexamic acid in melasma

A clinical observation study combines 1064-nm Q-switched fractional laser with oral tranexamic acid for melasma [7]. The rationale given is that 1064-nm Q-switched laser is widely used for pigmented disease because the wavelength is effectively absorbed by pigment, leading to damage of pigment and melanocytes [7]. The source notes that conventional 1064-nm Q-switched treatment required large flare and low-energy repeated scanning, with a terminal reaction of redness and a lesion temperature rise of 2 degrees C [7].

Combination topical regimen and post-inflammatory hyperpigmentation in skin of colour

A 12-week, single-centre, prospective, non-blinded, non-randomized study evaluates a comprehensive skincare regimen for reducing PIH in skin of colour patients [4]. The regimen centres on a Pigment Balancing Peel combining glycolic acid, lactic acid, kojic acid, vitamin C and emblica, supplemented over 11 weeks with a hydrating B5 gel, a discoloration defence product, an LHA cleansing gel and a brightening UV defence sunscreen [4]. Kojic acid appears here as one component among several rather than as a standalone marker [4][12].

Retinal and azelaic acid in blemish-prone skin with post-inflammatory hyperpigmentation

An eight-week randomized prospective split-face, vehicle-controlled study examined an anhydrous 0.1% retinal and 10% azelaic acid concentrate for blemish-prone skin [11]. The background given is that blemish-prone skin is driven by follicular hyperkeratinization, excessive sebum production, microbial dysbiosis and inflammation, often accompanied by post-inflammatory erythema and hyperpigmentation, and that retinal and azelaic acid have complementary mechanisms of action [11].

Effervescent glutathione formulation and facial dark spots

A randomized, double-blinded, single-centre, two-arm, placebo-controlled prospective study evaluates the clinical safety, efficacy and in-use tolerability of an effervescent glutathione tablet product in subjects with facial hyperpigmentation and dark spots, including pimple marks, sunspots, age spots and uneven skin tone [3]. The endpoints named are clinical safety, efficacy and in-use tolerability rather than a specific molecular marker [3].

Setmelanotide response variability in Bardet-Biedl syndrome after paediatric kidney transplantation

Setmelanotide is a melanocortin 4 receptor (MC4R) agonist studied in rare monogenic obesity conditions affecting the leptin-melanocortin signalling pathway [2]. In two children with genetically confirmed Bardet-Biedl syndrome treated after kidney transplantation, anthropometric, hunger, metabolic, graft-function, cyclosporine and genetic data were collected [1]. Patient 1, a 17-year-old boy with a homozygous pathogenic SDCCAG8 exon deletion, improved over 12 months: weight 55.6 to 48.0 kg, BMI 26.6 to 23.0 kg/m2, BMI-for-age z-score +1.60 to +0.43, maximal-hunger score 8/10 to 5/10, and HbA1c 6.5% to 5.1% [1].

Marker class	Example measure	Where reported
Clinical severity scale	POSAS	Post-surgical scar study [6]
Instrument colour measurement	Colorimeter (vascularity, hyperpigmentation)	Post-surgical scar study [6]
Enzymatic	Tyrosinase inhibition	Curcuma xanthorriza Roxb. trial [5]; kojic acid review [12]
Transcriptional	MITF expression	Curcuma xanthorriza Roxb. trial [5]
Melanin synthesis	Inhibition of melanin synthesis	Bakuchiol PIH study [8]

Setmelanotide in heterozygous PCSK1 deficiency

A case report describes a 40-year-old female with a heterozygous PCSK1 N221D (c.661 A>G) variant causing severe early-onset treatment-resistant obesity, with previous suboptimal response to bariatric surgery and conventional obesity medications, who achieved a total weight loss of 11.8% with setmelanotide [2]. The report states it is the first case in a patient with a heterozygous rather than homozygous PCSK1 variant [2].

Adrenal and thyroid markers in case reports

Two case reports describe endocrine findings in adolescents. One documents cytotoxic lesions of the corpus callosum secondary to Addison's disease in a 13-year-old girl, an association not previously reported [9]. The other describes persistent elevation of thyroid-stimulating hormone despite levothyroxine therapy revealing autoimmune adrenal insufficiency in an adolescent with autoimmune thyroiditis [10]. Neither report addresses pigmentation markers directly.

If you are reading this for personal health reasons

The materials described here are supplied for laboratory research use only, and we do not provide dosing or medical guidance. Nothing on this page is a recommendation for self-treatment of hyperpigmentation or any other condition. Anyone considering a compound for themselves should speak to a licensed clinician.